Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of GT103 in Combination With Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer

NCT05617313 is registered in ClinicalTrials.gov with Ryan Dackor as lead sponsor.

NCT NCT05617313
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05617313 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of GT103 in Combination With Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer
Lead sponsor
Ryan Dackor
Phase
Phase 2
Overall status
Terminated
Start date
February 17, 2023
Completion date
June 26, 2025
Enrollment
21 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic nsclc, non small cell lung cancer, recurrent non small cell lung cancer